FDA Approves Eli Lilly’s Omvoh for Crohn’s Disease Based on Phase III VIVID-1 Trial Outcomes
The FDA has approved Eli Lilly’s Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. The therapy is now approved for two types of inflammatory bowel disease (IBD) following its October 2023 approval …